The hospital Humanitas Gavazzeni in Bergamo, Italy has been evaluating the RayPilot system for electromagnetic intrafractional prostate tracking since 2012. In the end of 2013 the medical physicist Alessandro Vai with colleagues published a scientific poster with results at the AIFM congress in Turin.
The purpose of the work was to evaluate the intrafractional motion of the prostate and to assess the impact of this motion on the CTV-PTV margins. A diagram on the poster displays that RayPilot can register the organ motion in real-time and prostate motion of more than 1,5 cm during the treatment has been registered.
As a conclusion it is stated that including intrafractional motion the CTV-PTV margin will increase by 18% and the impact of intrafractional motion needs to be taken into account especially in hypofractionated protocols.
The RayPilot system has been in clinical use since 2010 and around 30 scientific papers, posters and oral presentations has been presented at scientific meetings and in literature such as the ESTRO, ASTRO, AAPM on national congresses and in The Green Journal. The latest poster from Humanitas Gavazzeni named: Real-time intrafraction target motion evaluation in prostate cancer radiotherapy using a temporary-implanted wired electromagnetic transmitter: influence on treatment margins could be viewed and downloaded from http://www.micropos.se/scientific/publications/
RayPilot is an electromagnetic tracking system and will during 2014 be updated with included in-situ dosimetry to be able to both track the position of and measure the administrated dose in the tumor region.
The RayPilot transmitter stays in the prostate for all fractions (2-12 weeks) and is removed after the final treatment.
For further information contact:
Tomas Gustafsson, CEO, Micropos Medical AB (publ), +46-31-772 80 99
About Micropos Medical AB (publ):
Micropos Medical AB (publ) (www.micropos.se) is a Swedish medical device company founded in 2003 as a result of four physicians’ long clinical experience in the therapeutic radiation oncology field. The company has developed the RayPilot® system for increased precision in radiotherapy of prostate cancer. The RayPilot® system is an electromagnetic positioning system that enables real time position of the prostate for a fast and objective set-up and for continuous positioning during the treatment. A precise and safe localization of the tumor can dramatically improve the outcome of the treatment, particularly for hypofractionated protocols. The RayPilot® system consists mainly of three parts; a transmitter that is placed in the ROI, a receiving system that is placed directly on any existing treatment coach and software that continuously shows where the tumor is and where to beam. The transmitter is removed after the final treatment in order to enable MRI follow-up.